uniQure stock eyes key AMT-130 update as Huntington’s gene therapy advances

uniQure stock (ISIN IL0011559904) is in the spotlight as of September 21, 2026, with investors watching the company’s Huntington’s disease gene therapy AMT-130 ahead of a planned four-year Phase 1/2 data update by the end of the third quarter. The program, which targets reduction of the mutant huntingtin protein, has already supported a biologics license application filed earlier in September 2026 using three-year clinical data.

AMT-130 update becomes the next major milestone

According to Yahoo Finance on September 21, 2026, uniQure has guided that a four-year update from its Phase 1/2 AMT-130 study in Huntington’s disease is expected by September 30, 2026, positioning the data as a near-term catalyst for the stock. The same report notes that uniQure recently submitted a biologics license application for AMT-130 using three-year clinical data compared with an external control, leaving the four-year update as the remaining quarter-end event.

The AMT-130 program aims to reduce production of the mutant huntingtin protein, which is central to the pathophysiology of Huntington’s disease, and the progression from three-year to four-year data gives investors a clearer view of durability and safety. For shareholders, this means the upcoming dataset could shift expectations around the therapy’s risk-benefit profile and the potential size and timing of any future revenue stream if the therapy reaches the market.

Pipeline focus and risk balance for uniQure stock

In the same sector overview, Yahoo Finance highlights that the AMT-130 filing relied on three-year data compared against an external control group, underlining how uniQure is leveraging long-term follow-up to support its regulatory case. This structure means that the four-year readout will not only add a fourth year of efficacy and safety observations but will also test the robustness of the external-control-based comparisons that underpin the biologics license application.

For a mid-cap biotechnology company, a single late-stage gene therapy can have an outsized impact on valuation, and uniQure is no exception. With AMT-130 already at the BLA submission stage based on three-year data and a four-year update coming by quarter-end, the pipeline’s concentration around this program increases both upside and downside: positive durability and safety trends could support partnership or commercial planning, while weaker-than-expected outcomes could weigh on sentiment and push investors to reassess the long-term revenue potential.

Stock perspective around the upcoming data

As of the latest available trading data in September 2026, uniQure stock trades on Nasdaq in United States dollars, with the quote reflecting expectations for the AMT-130 program and broader biotech risk appetite. The market capitalization, also measured in United States dollars as of a recent trading day in September 2026, places uniQure in the mid-cap biotechnology range, underscoring that a successful gene therapy launch could materially change the company’s financial profile over time.

For investors, the key near-term checkpoint is the four-year AMT-130 Phase 1/2 update expected by September 30, 2026, which follows the three-year data already used in the biologics license application and provides a numerical comparison of durability over an additional year of follow-up. The balance of risk and opportunity around that event, together with any subsequent regulatory feedback, is likely to be the main driver for uniQure stock in the coming weeks and months.

More news and analyses on uniQure stock